Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1125976 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1125976 [once daily, dose-esc.] | EXPERIMENTAL | Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities |
| BAY1125976 [twice daily, dose-esc.] | EXPERIMENTAL | Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities |
| BAY1125976 [MTD] | EXPERIMENTAL | Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups |
| Name | Type | Description |
|---|---|---|
| BAY1125976 | DRUG | Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities |
Inclusion Criteria: * For dose escalation cohorts: Subjects with advanced, histologically or cytologically confirmed solid tumors are eligible. Subjects' tumors (all comers) must be refractory to standard treatment with no standard therapy available, or subjects actively refuse any treatment, which...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
BAY1125976 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed as a potential oncology therapy, though it is still in clinical development and not yet approved for any use.
BAY1125976 is an allosteric AKT 1/2 inhibitor. It targets the AKT1 and AKT2 proteins, which are part of the PI3K/AKT signaling pathway involved in cell growth and survival. By inhibiting these targets, the drug aims to interfere with cancer cell proliferation.
BAY1125976 is being developed by Bayer AG, a multinational pharmaceutical company headquartered in Germany. Bayer's stock is traded on the OTC market under the ticker symbol BAYRY.
BAY1125976 is in Phase 1 clinical development. It has completed a Phase 1 dose escalation study, but it remains investigational and has not received FDA approval. The drug is still in the early stages of clinical testing.
BAY1125976 has been studied in one clinical trial, NCT01915576, a Phase 1 dose escalation study in patients with neoplasms. This trial enrolled 79 participants and was conducted in the United States, France, Germany, and Switzerland. The trial has been completed.
No alternative names for BAY1125976 have been disclosed. The drug is identified by its compound code BAY1125976 in clinical and research settings.